Whelton A. Miller III

According to our database, Whelton A. Miller III authored at least 6 papers between 2019 and 2025.

Collaborative distances:

• Dijkstra number of four.
• Erdős number of five.

2025

AICpred: Machine Learning-Based Prediction of Potential Anti-Inflammatory Compounds Targeting TLR4-MyD88 Binding Mechanism.

Lucindah N. Fry-Nartey, Cyril Akafia, Ursula S. Nkonu, Spencer B. Baiden, Ignatus Nunana Dorvi, Kwasi Agyenkwa-Mawuli, Odame Agyapong, Claude Fiifi Hayford, Michael D. Wilson, Whelton A. Miller III, Samuel K. Kwofie

Inf., 2025

2024

Structure-Based Discovery of Potential HPV E6 and EBNA1 Inhibitors: Implications for Cervical Cancer Treatment.

Emmanuel Broni, Carolyn Ashley, Miriam Velazquez, Patrick O. Sakyi, Samuel K. Kwofie, Whelton A. Miller III

Comput., June, 2024

Design of Inhibitors That Target the Menin-Mixed-Lineage Leukemia Interaction.

Moses N. Arthur, Kristeen Bebla, Emmanuel Broni, Carolyn Ashley, Miriam Velazquez, Xianin Hua, Ravi Radhakrishnan, Samuel K. Kwofie, Whelton A. Miller III

Comput., January, 2024

2021

Pharmacophore-Guided Identification of Natural Products as Potential Inhibitors of Mycobacterium ulcerans Cystathionine γ-Synthase MetB.

Samuel K. Kwofie, Nigel N. O. Dolling, Emmanuel Donkoh, Godwin M. Laryea, Lydia Mosi, Whelton A. Miller III, Michael B. Adinortey, Michael D. Wilson

Comput., 2021

2020

Molecular docking and dynamics simulations studies of OmpATb identifies four potential novel natural product-derived anti-<i>Mycobacterium tuberculosis</i> compounds.

Samuel K. Kwofie, Courage Adobor, Erasmus Quansah, Joana Bentil, Michael Ampadu, Whelton A. Miller III, Michael D. Wilson

Comput. Biol. Medicine, 2020

2019

Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24.

Samuel K. Kwofie, Emmanuel Broni, Joshua Teye, Erasmus Quansah, Ibrahim Issah, Michael D. Wilson, Whelton A. Miller III, Elvis K. Tiburu, Joseph H. K. Bonney

Comput. Biol. Medicine, 2019